Researchers have developed malaria vaccines using genetically modified Plasmodium falciparum parasites treated with radiation and chemicals, that grow in the liver but are blocked from reaching the blood stage. This late liver-stage arrest exposes the immune system to more parasite proteins, which "may" increase protection. Early goals are 90–95% effectiveness with fewer parasites per dose, potentially lowering vaccine cost, and the vaccines are being developed specifically for children in "high

Plasmodium species (Malaria): Video, Causes, & Meaning | Osmosis

Malaria Plasmodium Life Cycle